Trial reportBMC nephrology2018
Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
Trial report in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial.Blood advances · 2020Trial
- A Multivariable Prediction Model for Early Mortality in Multiple Myeloma Patients With Renal Impairment.Cancer medicine · 2026Article
- [Renal response and prognosis of newly diagnosed patients with multiple myeloma with renal impairment applying VRD and autologous hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Clinical and Renal Outcomes in Multiple Myeloma with Involved Free Light Chains Exceeding 1000 mg/L at Diagnosis: Insights from an Indian Cohort.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study.Clinical and experimental medicine · 2025Article
- Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma.Annals of hematology · 2025Article
- The Urine Light Chain/eGFR Quotient as a Tool to Rule out Cast Nephropathy in Myeloma-Associated Kidney Failure.Biomedicines · 2024Article
- Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies.Antibodies (Basel, Switzerland) · 2024Review
- Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view.Clinical kidney journal · 2023Article
- Multiple myeloma with acute light chain cast nephropathy.Blood cancer journal · 2023Review
- High prevalence of Wilms tumor 1 expression in multiple myeloma and plasmacytoma: A cohort of 142 Asian patients' samples.Pathology oncology research : POR · 2023Article
- A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis.BMC nephrology · 2022Article
- Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study.Biomedicines · 2022Article
- Effect of high cut-off dialysis for acute kidney injury secondary to cast nephropathy in patients with multiple myeloma: a systematic review and meta-analysis.Clinical kidney journal · 2021Article
- Kidney injury and disease in patients with haematological malignancies.Nature reviews. Nephrology · 2021Review
- Light chain myeloma and detection of free light chains in serum and urine of dogs and cats.Journal of veterinary internal medicine · 2021Article
- C3 glomerulonephritis along with light chain proximal tubulopathy without crystal deposits in multiple myeloma: a case report.World journal of surgical oncology · 2021Article
- New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies.Journal of clinical medicine · 2020Review
- Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study.Blood cancer journal · 2020Article
- Perspectives From an Onconephrology Interest Group: Conference Report.Canadian journal of kidney health and disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundRenal impairment (RI) is common in multiple myeloma (MM) and is associated with poor survival. This study reports the associations between renal function and disease characteristics including serum free light chain (FLC) level at diagnosis in patients with MM.
methodsUsing data from the Medical Research Council Myeloma IX trial, a multicentre, randomized, open-label, phase III and factorial-design trial, we assessed the relationships between renal function, demographic, and disease characteristics, including serum FLC levels, in 1595 newly diagnosed MM patients. Multivariable linear regression was utilised to identify factors that were associated with renal function at diagnosis. A receiver operating characteristic curve (ROC) was used to identify the optimal threshold for serum FLC level at diagnosis to predict severe RI.
results52.8% of patients had an estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73 m
conclusionThere was a strong relationship between higher serum FLC levels at diagnosis and the severity of RI that was irrespective of the paraprotein type. We report an increased risk of severe RI in patients presenting with serum FLC levels above 800 mg/L at diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.